Patients Treated With Sunitinib And Sorafenib Respond To Flu Vaccine

Friday, Jan. 13th 2012 6:40 AM

Patients treated with sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared, according to a study in Clinical Cancer Research, a journal of the American Association for Cancer Research. Keith Flaherty, M.D., director of developmental therapeutics at the Massachusetts General Hospital and a senior editor of Clinical Cancer Research, said the findings have broad implications beyond questions of patient management.

VN:F [1.9.22_1171]
Rating: 5.0/5 (1 vote cast)
VN:F [1.9.22_1171]
Rating: 0 (from 0 votes)
Patients Treated With Sunitinib And Sorafenib Respond To Flu Vaccine, 5.0 out of 5 based on 1 rating
Posted on Friday, Jan. 13th 2012 6:40 AM | by Share of Cost | in Share of Cost | No Comments »

Leave a Reply